EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

FDA approvals of specialty drugs, 2000-2024

Sophie E Knox, Claire H Brennan iD, Daniel E Enright, Peter J Neumann iD, James D Chambers iD

Health Affairs Scholar · 04.02.2026 · 4 (2)

DOI: 10.1093/haschl/qxag035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Health Affairs Scholar, online erschienen am 07.02.2026. Verfasst von Sophie E Knox und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, M…. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sophie E Knox, Mpharm, Claire H Brennan, BA, Daniel E Enright, MS, Peter J Neumann, ScD, James D Chambers, PhD; FDA Approvals of Specialty Drugs, 2000-2024

Autor:innen und Institutionen

  • The Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA 02111, United States.

ORCID-Profile: Claire H Brennan, Peter J Neumann, James D Chambers

Zitieren

APA

Knox, S. E., Brennan, C. H., Enright, D. E., Neumann, P. J., & Chambers, J. D. (2026). FDA approvals of specialty drugs, 2000-2024. Health Affairs Scholar, 4(2). https://doi.org/10.1093/haschl/qxag035

Vancouver

Knox SE, Brennan CH, Enright DE, Neumann PJ, Chambers JD. FDA approvals of specialty drugs, 2000-2024. Health Affairs Scholar. 2026;4(2). doi:10.1093/haschl/qxag035

BibTeX
@article{Knox2026,
  author = {Knox, Sophie E and Brennan, Claire H and Enright, Daniel E and Neumann, Peter J and Chambers, James D},
  title = {FDA approvals of specialty drugs, 2000-2024},
  journal = {Health Affairs Scholar},
  year = {2026},
  volume = {4},
  number = {2},
  doi = {10.1093/haschl/qxag035}
}
Kostenlos starten →